



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 7548

SERIAL NUMBER 10/596,521	FILING OR 371(c) DATE 06/15/2006 RULE	CLASS 548	GROUP ART UNIT 1626	ATTORNEY DOCKET NO. TIP-0063USPCT
APPLICANTS Jean-Francois Bonfanti, Ande, FRANCE; Koenraad Jozef Lodewijk Andries, Beerse, BELGIUM; Jerome Michel Claude Fortin, Igoville, FRANCE; Philippe Muller, Ande, FRANCE; Frederic Marc Maurice Doublet, Isneauville, FRANCE; Christophe Meyer, Port St Ouen, FRANCE; Rudy Edmond Willebrords, Merksplas, BELGIUM; Tom Valverius Josepha Gevers, Vosselaar, BELGIUM; Philip Maria Martha Bern Timmerman, Hasselt, BELGIUM;				
** CONTINUING DATA ***** This application is a 371 of PCT/EP04/53618 12/20/2004 which claims benefit of 60/566,867 04/30/2004				
** FOREIGN APPLICATIONS ***** EUROPEAN PATENT OFFICE (EPO) 03104806.9 12/18/2003				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 01/16/2007				
Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after met Verified and Acknowledged <input checked="" type="checkbox"/> Allowance Examiner's Signature: _____ Initials: _____		STATE OR COUNTRY FRANCE	SHEETS DRAWING 0	TOTAL CLAIMS 37
INDEPENDENT CLAIMS 1				
ADDRESS 27777				
TITLE 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication				
FILING FEE RECEIVED 1750	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	